Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Verrica Pharmaceuticals Inc.

Clinicaltrial registered20 Oct 2026

Verrica Pharmaceuticals Inc.

20 Oct 2026: Trial registered · Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5). Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
20 Oct 2026
Title
Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)
Conditions
Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Phase
Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
United States
Country
United States
Reference
NCT07881952
Location
United States
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Verrica Pharmaceuticals Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from United States

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.